Local view for "http://purl.org/linkedpolitics/eu/plenary/2006-09-28-Speech-4-023"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2006-09-28"^^xsd:date2
dcterms:Is Part Of	lp_eu:Nanosciences and nanotechnology (debate)2
dcterms:Language	"nl"^^xsd:language2
lpv:document identification number	"en.20060928.4.4-023"2
lpv:hasSubsequent	lp_eu:2006-09-28-Speech-4-0242
lpv:speaker	lp:Bas Belder2
lpv:spokenAs	member; Delegation to the EU-Bulgaria Joint Parliamentary Committee (2004-09-15--2006-12-31)3 member; IND/DEM (2004-07-20--2009-07-13)3 substitute; REGI (2004-09-15--2007-01-14)3 substitute; AFCO (2004-09-15--2007-01-14)3 substitute; Delegation for relations with the United States (2004-09-23--2007-03-13)3 vice-chair; Delegation for relations with Israel (2004-09-20--2007-03-13)3 member; AFET (2004-07-21--2007-01-14)3 substitute; INTA (2004-07-21--2007-01-14)3 unknown; ChristenUnie - Staatkundig Gereformeerde Parti (2004-07-20--2009-07-13)3
lpv:translated text	"Mr President, it is vitally important that attention be given to nanotechnology. The production of new material at the molecular level results in the creation of new characteristics, the effects of which on human health and on the environment are as yet unknown. The Commission has produced a proposal for an action plan to run until 2009, which is full of high expectations of the economic and social benefits, but the Commission regards the public's ethical misgivings and concerns mainly as obstacles, and so, Commissioner, in that respect, I have to tell you that the action plan is particularly unbalanced. The same, unfortunately, can be said of the Ransdorf report, even though it does, to some extent, act as a counterbalance. What, then, is missing? What is absent, above all, is the willingness to consider concerns other than safety risks, not least the issue of whether or not new technologies are desirable, or issues to do with people’s convictions about life in general. The benefits and possible adverse effects must first of all be considered, in order to prevent choices being made solely on the basis of economic value while the technology is still at an early stage in its development. Secondly, we in the European Union must concentrate more on international coordination, not only as regards toxicity tests and risk assessments across the whole life cycle, but also as regards legislation on standards, labelling and liability, with those who market nanoparticles being liable for any damage caused by them. Finally, one has to consider the desirability or otherwise of patents relating to nanotechnologies and nanomaterials, particularly with regard to basic and general technology and to materials capable of being used in a wide variety of different ways. Can the Commission have a critical analysis done of this? It might then consider the question of to what extent the patents and licenses would put poorer countries at a still greater disadvantage and what might be done to counteract this."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph